ArticleOphthalmology and therapy2026
Stereophotographic Assessment of Intraocular Pressure Reduction in Myopic Eyes with Glaucoma-Compatible Optic Neuropathy.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe aim of our work is to evaluate stereoscopic photographic changes in the optic nerve head among patients with glaucoma-compatible optic neuropathy in myopia (GCON-M) after intraocular pressure (IOP) reduction and to determine whether these changes represent true progressive glaucomatous damage.
methodsThis self-controlled, observational cohort study included 41 patients with bilateral normal-tension GCON-M. The eye with the worse baseline visual field (VF) mean deviation received intraocular pressure (IOP)-lowering treatment targeting a 30% reduction, while the fellow eye served as an untreated control. Participants underwent serial VF testing and stereophotographic imaging over a median follow-up of 48 months. Structural and functional progression was compared between the treated and control eyes.
resultsAmong the 41 patients (82 eyes), the treatment group achieved a mean IOP reduction of 31.1%, significantly greater than that in the control group (P < 0.001). There was no significant difference between the groups in the change in VF mean deviation (P = 0.25) or structural progression scores (P = 0.37). Disease progression occurred in 9.7% of treated and 12.2% of control eyes. Kaplan-Meier analysis showed no significant difference in progression-free survival between the groups (P = 0.76), which was further confirmed by multivariate Cox regression analysis (P = 0.67).
conclusionsThe long-term stability of GCON-M in many untreated eyes suggests that these changes may represent non-progressive remodeling rather than true glaucomatous damage. These findings argue against routine glaucoma therapy and support an individualized monitoring strategy to avoid overtreatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.